Your browser doesn't support javascript.
loading
Tachyphylaxis and reproducibility of desmopressin response in perioperative persons with nonsevere hemophilia A: implications for clinical practice.
Romano, L G R; Schütte, L M; van Hest, R M; Meijer, K; Laros-van Gorkom, B A P; Nieuwenhuizen, L; Eikenboom, J; Heubel-Moenen, F C J I; Uitslager, N; Coppens, M; Fijnvandraat, K; Driessens, M H E; Polinder, S; Cnossen, M H; Leebeek, F W G; Mathôt, R A A; Kruip, M J H A.
Afiliación
  • Romano LGR; Department of Hematology, Erasmus MC, Erasmus University Medical Center, Rotterdam, The Netherlands.
  • Schütte LM; Department of Hematology, Erasmus MC, Erasmus University Medical Center, Rotterdam, The Netherlands.
  • van Hest RM; Department of Hospital Pharmacy and Clinical Pharmacology, Amsterdam University Medical Centers - University of Amsterdam, Amsterdam, The Netherlands.
  • Meijer K; Department of Hematology, University Medical Center Groningen, Groningen, The Netherlands.
  • Laros-van Gorkom BAP; Department of Hematology, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Nieuwenhuizen L; Department of Hematology, Máxima Medical Center, Veldhoven, The Netherlands.
  • Eikenboom J; Department of Internal Medicine, Division of Thrombosis and Hemostasis, Leiden University Medical Center, Leiden, The Netherlands.
  • Heubel-Moenen FCJI; Department of Hematology, Maastricht University Medical Center+, Maastricht, The Netherlands.
  • Uitslager N; Van Creveldkliniek, University Medical Center Utrecht, Utrecht, The Netherlands.
  • Coppens M; Department of Hematology, Amsterdam University Medical Centers - University of Amsterdam, Amsterdam, The Netherlands.
  • Fijnvandraat K; Pulmonary Hypertension & Thrombosis, Amsterdam Cardiovascular Sciences, Amsterdam, The Netherlands.
  • Driessens MHE; Department of Paediatric Hematology, Amsterdam University Medical Centers - University of Amsterdam, Emma Children's Hospital, Amsterdam, The Netherlands.
  • Polinder S; Department of Plasma Proteins, Sanquin Research, Amsterdam, The Netherlands.
  • Cnossen MH; Netherlands Hemophilia Patient Society, Nijkerk, The Netherlands.
  • Leebeek FWG; Department of Public Health, Erasmus MC, Erasmus University Medical Center, Rotterdam, The Netherlands.
  • Mathôt RAA; Department of Pediatric Hematology, Erasmus MC - Sophia Children's Hospital, Erasmus University Medical Center, Rotterdam, The Netherlands.
  • Kruip MJHA; Department of Hematology, Erasmus MC, Erasmus University Medical Center, Rotterdam, The Netherlands.
Res Pract Thromb Haemost ; 8(3): 102367, 2024 Mar.
Article en En | MEDLINE | ID: mdl-38660455
ABSTRACT

Background:

Desmopressin is frequently used perioperatively in persons with nonsevere hemophilia A. However, increase in factor (F)VIIIC after desmopressin use is interindividually highly variable. Tachyphylaxis has only been reported in test setting for persons with hemophilia A, with a remaining response of approximately 70% after a second dose compared with that after a first dose.

Objectives:

To study tachyphylaxis of FVIIIC response after multiple administration(s) of desmopressin in perioperative persons with nonsevere hemophilia A.

Methods:

We studied FVIIIC levels after desmopressin before (day 0 [D0]) and on days 1 (D1) and 2 (D2) after surgery in 26 patients of the DAVID and Little DAVID studies. We studied tachyphylaxis by comparing the responses at D1 and D2 with that at D0. We also assessed the reproducibility of the D0 response in comparison to an earlier performed desmopressin test.

Results:

The median absolute FVIIIC increase was 0.50 IU/mL (0.35-0.74; n = 23) at D0, 0.21 IU/mL (0.14-0.28; n = 17) at D1, and 0.23 IU/mL (0.16-0.30; n = 11) at D2. The median percentage of FVIII increase after the second administration (D1) compared with the first (D0) was 42.9% (29.2%-52.5%; n = 17) and that of the third (D2) compared with the first (D0) was 36.4% (23.7%-46.9%; n = 11). The FVIIIC desmopressin response at D0 was comparable with the desmopressin test response in 74% of the patients.

Conclusion:

Tachyphylaxis in the surgical setting was considerably more pronounced than previously reported, with FVIIIC at D1 and D2 of 36% to 43% of the initial response. Our results may have important implications for monitoring repeated desmopressin treatment when used perioperatively.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Res Pract Thromb Haemost Año: 2024 Tipo del documento: Article País de afiliación: Países Bajos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Res Pract Thromb Haemost Año: 2024 Tipo del documento: Article País de afiliación: Países Bajos